NASDAQ:RTTR - Ritter Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.76 -0.07 (-8.43 %)
(As of 01/16/2019 01:21 AM ET)
Previous Close$0.83
Today's Range$0.73 - $0.88
52-Week Range$0.47 - $4.00
Volume606,500 shs
Average Volume198,110 shs
Market Capitalization$4.64 million
P/E Ratio-0.16
Dividend YieldN/A
Beta1.45
Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTTR
CUSIPN/A
Phone310-203-1000

Debt

Current Ratio5.08
Quick Ratio5.08

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Book Value$3.03 per share
Price / Book0.25

Profitability

Net Income$-7,860,000.00
Net MarginsN/A
Return on Assets-84.58%

Miscellaneous

Employees9
Market Cap$4.64 million
OptionableNot Optionable

Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Shares of Ritter Pharmaceuticals reverse split before market open on Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its quarterly earnings results on Friday, November, 9th. The biotechnology company reported ($0.83) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.84) by $0.01. View Ritter Pharmaceuticals' Earnings History.

When is Ritter Pharmaceuticals' next earnings date?

Ritter Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Ritter Pharmaceuticals.

What price target have analysts set for RTTR?

2 analysts have issued 1 year price objectives for Ritter Pharmaceuticals' stock. Their predictions range from $15.00 to $15.00. On average, they expect Ritter Pharmaceuticals' stock price to reach $15.00 in the next year. This suggests a possible upside of 1,873.7% from the stock's current price. View Analyst Price Targets for Ritter Pharmaceuticals.

What is the consensus analysts' recommendation for Ritter Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ritter Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ritter Pharmaceuticals.

What are Wall Street analysts saying about Ritter Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ritter Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. " (11/16/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $4.30. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, topsalysin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (8/15/2018)

Has Ritter Pharmaceuticals been receiving favorable news coverage?

News stories about RTTR stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ritter Pharmaceuticals earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of Ritter Pharmaceuticals' key competitors?

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:
  • Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 35)
  • Mr. Michael D. Step, Consultant & Director (Age 58)
  • Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 58)
  • Mr. Jeffrey Benjamin, Principal Financial & Accounting Officer (Age 53)
  • Ms. Robin Schmidt, Director of Clinical Operations

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

How do I buy shares of Ritter Pharmaceuticals?

Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $0.76.

How big of a company is Ritter Pharmaceuticals?

Ritter Pharmaceuticals has a market capitalization of $4.64 million. The biotechnology company earns $-7,860,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Ritter Pharmaceuticals employs 9 workers across the globe.

What is Ritter Pharmaceuticals' official website?

The official website for Ritter Pharmaceuticals is http://www.ritterpharmaceuticals.com.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]


MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: No Load Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel